Mitochondria-Targeted Antioxidants: A Step Towards Disease Treatment

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2020 Dec 23

PMID 33354280

Citations 47

Authors

Qian Jiang

Jie Yin

Jiashun Chen

Xiaokang Ma

Miaomiao Wu

Gang Liu

Kang Yao

Bie Tan

Yulong Yin

Affiliations

Soon will be listed here.

Abstract

Mitochondria are the main organelles that produce adenosine 5'-triphosphate (ATP) and reactive oxygen species (ROS) in eukaryotic cells and meanwhile susceptible to oxidative damage. The irreversible oxidative damage in mitochondria has been implicated in various human diseases. Increasing evidence indicates the therapeutic potential of mitochondria-targeted antioxidants (MTAs) for oxidative damage-associated diseases. In this article, we introduce the advantageous properties of MTAs compared with the conventional (nontargeted) ones, review different mitochondria-targeted delivery systems and antioxidants, and summarize their experimental results for various disease treatments in different animal models and clinical trials. The combined evidence demonstrates that mitochondrial redox homeostasis is a potential target for disease treatment. Meanwhile, the limitations and prospects for exploiting MTAs are discussed, which might pave ways for further trial design and drug development.

Citing Articles

Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential.

Fonseka O, Gare S, Chen X, Zhang J, Alatawi N, Ross C Cells. 2025; 14(5).

PMID: 40072053 PMC: 11899429. DOI: 10.3390/cells14050324.

Global research trends on the associations between chronic kidney disease and mitochondria: insights from the bibliometric analysis.

Tang X, Zhang A, Feng X, Wang W, Chen F, Tao Y Int Urol Nephrol. 2025; .

PMID: 40019610 DOI: 10.1007/s11255-025-04437-x.

Mitochondrial Dysfunction and Its Potential Molecular Interplay in Hypermobile Ehlers-Danlos Syndrome: A Scoping Review Bridging Cellular Energetics and Genetic Pathways.

Shirvani P, Shirvani A, Holick M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996855 PMC: 11854588. DOI: 10.3390/cimb47020134.

4-Aminoquinoline as a privileged scaffold for the design of leishmanicidal agents: structure-property relationships and key biological targets.

Romero A, Delgado F Front Chem. 2025; 12:1527946.

PMID: 39981131 PMC: 11841433. DOI: 10.3389/fchem.2024.1527946.

Oxidative Stress Induced by Antivirals: Implications for Adverse Outcomes During Pregnancy and in Newborns.

Costa B, Gouveia M, Vale N Antioxidants (Basel). 2025; 13(12.

PMID: 39765846 PMC: 11727424. DOI: 10.3390/antiox13121518.

References

Miura Y . Oxidative stress, radiation-adaptive responses, and aging. J Radiat Res. 2004; 45(3):357-72. DOI: 10.1269/jrr.45.357. View

Fan J, Shek P, Suntres Z, Li Y, Oreopoulos G, Rotstein O . Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery. 2000; 128(2):332-8. DOI: 10.1067/msy.2000.108060. View

Fernandez-Gajardo R, Matamala J, Carrasco R, Gutierrez R, Melo R, Rodrigo R . Novel therapeutic strategies for traumatic brain injury: acute antioxidant reinforcement. CNS Drugs. 2014; 28(3):229-48. DOI: 10.1007/s40263-013-0138-y. View

Zhan W, Liao X, Li L, Chen Z, Tian T, Yu L . In vitro mitochondrial-targeted antioxidant peptide induces apoptosis in cancer cells. Onco Targets Ther. 2019; 12:7297-7306. PMC: 6738130. DOI: 10.2147/OTT.S207640. View

Hou S, Yang Y, Zhou S, Kuang X, Yang Y, Gao H . Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss. Biomater Sci. 2018; 6(6):1627-1635. DOI: 10.1039/c7bm01181d. View

Tauskela J . MitoQ--a mitochondria-targeted antioxidant. IDrugs. 2007; 10(6):399-412. View

Cai J, Jiang Y, Zhang M, Zhao H, Li H, Li K . Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury. J Physiol Biochem. 2018; 74(2):335-343. DOI: 10.1007/s13105-018-0617-1. View

Isaev N, Novikova S, Stelmashook E, Barskov I, Silachev D, Khaspekov L . Mitochondria-targeted plastoquinone antioxidant SkQR1 decreases trauma-induced neurological deficit in rat. Biochemistry (Mosc). 2012; 77(9):996-9. DOI: 10.1134/S0006297912090052. View

Finichiu P, Larsen D, Evans C, Larsen L, Bright T, Robb E . A mitochondria-targeted derivative of ascorbate: MitoC. Free Radic Biol Med. 2015; 89:668-78. PMC: 4698375. DOI: 10.1016/j.freeradbiomed.2015.07.160. View

10.

Ho U, Luff J, James A, Lee C, Quek H, Lai H . SMG1 heterozygosity exacerbates haematopoietic cancer development in Atm null mice by increasing persistent DNA damage and oxidative stress. J Cell Mol Med. 2019; 23(12):8151-8160. PMC: 6850945. DOI: 10.1111/jcmm.14685. View

11.

Sabbah H, Gupta R, Singh-Gupta V, Zhang K, Lanfear D . Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide. Cardiovasc Drugs Ther. 2018; 32(4):319-328. PMC: 6133191. DOI: 10.1007/s10557-018-6805-y. View

12.

Ooi B, Goh B, Yap W . Oxidative Stress in Cardiovascular Diseases: Involvement of Nrf2 Antioxidant Redox Signaling in Macrophage Foam Cells Formation. Int J Mol Sci. 2017; 18(11). PMC: 5713305. DOI: 10.3390/ijms18112336. View

13.

Galdiero S, Gomes P . Peptide-Based Drugs and Drug Delivery Systems. Molecules. 2018; 22(12). PMC: 6149859. DOI: 10.3390/molecules22122185. View

14.

Rezaei-Sadabady R, Eidi A, Zarghami N, Barzegar A . Intracellular ROS protection efficiency and free radical-scavenging activity of quercetin and quercetin-encapsulated liposomes. Artif Cells Nanomed Biotechnol. 2014; 44(1):128-34. DOI: 10.3109/21691401.2014.926456. View

15.

Yamada Y, Furukawa R, Yasuzaki Y, Harashima H . Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol Ther. 2011; 19(8):1449-56. PMC: 3149179. DOI: 10.1038/mt.2011.99. View

16.

Szarka N, Pabbidi M, Amrein K, Czeiter E, Berta G, Pohoczky K . Traumatic Brain Injury Impairs Myogenic Constriction of Cerebral Arteries: Role of Mitochondria-Derived HO and TRPV4-Dependent Activation of BK Channels. J Neurotrauma. 2017; 35(7):930-939. PMC: 5865628. DOI: 10.1089/neu.2017.5056. View

17.

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J . Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017; 117(15):10043-10120. PMC: 5611849. DOI: 10.1021/acs.chemrev.7b00042. View

18.

Krainz T, Gaschler M, Lim C, Sacher J, Stockwell B, Wipf P . A Mitochondrial-Targeted Nitroxide Is a Potent Inhibitor of Ferroptosis. ACS Cent Sci. 2016; 2(9):653-659. PMC: 5043442. DOI: 10.1021/acscentsci.6b00199. View

19.

Clark R, Empey P, Bayir H, Rosario B, Poloyac S, Kochanek P . Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. PLoS One. 2017; 12(7):e0180280. PMC: 5501440. DOI: 10.1371/journal.pone.0180280. View

20.

Picard M, Wallace D, Burelle Y . The rise of mitochondria in medicine. Mitochondrion. 2016; 30:105-16. PMC: 5023480. DOI: 10.1016/j.mito.2016.07.003. View